Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus - PubMed (original) (raw)
. 2007 Jan;122(1):115-20.
doi: 10.1016/j.clim.2006.10.003. Epub 2006 Nov 7.
Affiliations
- PMID: 17085075
- DOI: 10.1016/j.clim.2006.10.003
Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus
Yin Su et al. Clin Immunol. 2007 Jan.
Abstract
Objective: To investigate the role of anti-nucleosome antibodies (AnuA) in systemic lupus erythematosus (SLE).
Methods: IgG anti-nucleosome antibodies were detected by enzyme-linked immunosorbent assay (ELISA) in the sera of 233 SLE and 220 other rheumatic diseases' patients as well as 31 health controls. The patients were also evaluated for clinical and biological parameters.
Results: (1) Out of 233 SLE patients, 144 (61.8%) were seropositive for AnuA, which was significantly higher than that of patients with other rheumatic diseases [2.7% (6/220), P < 0.001]; the sensitivities and specificities of AnuA in SLE were 61.8% and 97.6%, respectively. (2) The positive rated of AnuA in SLE lacking of anti-DNP, anti-cmDNA, anti-Sm and anti-dsDNA antibodies were 57.1%, 55.9%, 62.4% and 51.2%, respectively. (3) The frequency of the fever, skin rash, and arthralgia were significantly higher in 144 positive AnuA SLE than those in AnuA negative SLE (P < 0.05). The frequency of leukopenia, elevations of ESR and CRP, lower C3/C4 levels and proteinuria in AnuA positive groups was significantly higher than that of AnuA negative groups (P < 0.05). (4) Level of AnuA was strongly correlated with the SLEDAI scores (r = 0.385, P < 0.001). Patients with active SLE showed significantly higher positive rate of AnuA (66.1%) than those with inactive disease (45.7%) (chi2 = 6.568, P = 0.010).
Conclusions: AnuA is one of the most valuable markers in the diagnosis of SLE lacking of anti-dsDNA, anti-Sm, anti-DNP and anti-cmDNA antibodies. The level of AnuA is associated with the disease activity of SLE.
Similar articles
- Anti-nucleosome antibodies as a disease activity marker in patients with systemic lupus erythematosus.
Suleiman S, Kamaliah D, Nadeem A, Naing NN, Che Maraina CH. Suleiman S, et al. Int J Rheum Dis. 2009 Jul;12(2):100-6. doi: 10.1111/j.1756-185X.2009.01391.x. Int J Rheum Dis. 2009. PMID: 20374326 - Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies.
Pradhan VD, Patwardhan MM, Ghosh K. Pradhan VD, et al. Indian J Dermatol Venereol Leprol. 2010 Mar-Apr;76(2):145-9. doi: 10.4103/0378-6323.60558. Indian J Dermatol Venereol Leprol. 2010. PMID: 20228543 - Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker.
Simón JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sánchez-Guerrero J. Simón JA, et al. Rheumatology (Oxford). 2004 Feb;43(2):220-4. doi: 10.1093/rheumatology/keh024. Epub 2003 Sep 16. Rheumatology (Oxford). 2004. PMID: 13130152 - Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis.
Bizzaro N, Villalta D, Giavarina D, Tozzoli R. Bizzaro N, et al. Autoimmun Rev. 2012 Dec;12(2):97-106. doi: 10.1016/j.autrev.2012.07.002. Epub 2012 Jul 15. Autoimmun Rev. 2012. PMID: 22810055 Review. - [Role of the nucleosome in the physiopathology of systemic lupus erythematosus].
Amoura Z, Piette JC. Amoura Z, et al. Ann Med Interne (Paris). 2003 Feb;154(1):25-32. Ann Med Interne (Paris). 2003. PMID: 12746656 Review. French.
Cited by
- Clinical and serological correlates of antinucleosome antibodies in South Africans with systemic lupus erythematosus.
Tikly M, Gould T, Wadee AA, van der Westhuizen E, Mokgethwa BBN. Tikly M, et al. Clin Rheumatol. 2007 Dec;26(12):2121-2125. doi: 10.1007/s10067-007-0637-7. Epub 2007 May 22. Clin Rheumatol. 2007. PMID: 17516129 - Diagnosis and early detection of CNS-SLE in MRL/lpr mice using peptide microarrays.
Williams S, Stafford P, Hoffman SA. Williams S, et al. BMC Immunol. 2014 Jun 7;15:23. doi: 10.1186/1471-2172-15-23. BMC Immunol. 2014. PMID: 24908187 Free PMC article. - High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus.
Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M. Abdulahad DA, et al. Arthritis Res Ther. 2011 May 6;13(3):R71. doi: 10.1186/ar3332. Arthritis Res Ther. 2011. PMID: 21548924 Free PMC article. - Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity.
Andrejevic S, Jeremic I, Sefik-Bukilica M, Nikolic M, Stojimirovic B, Bonaci-Nikolic B. Andrejevic S, et al. Clin Rheumatol. 2013 Nov;32(11):1619-26. doi: 10.1007/s10067-013-2330-3. Epub 2013 Jul 16. Clin Rheumatol. 2013. PMID: 23857662 - An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management.
Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, Zeb S, Tariq MA, Patlolla SR, Ali J, Hashim SN, Hashim S. Ameer MA, et al. Cureus. 2022 Oct 15;14(10):e30330. doi: 10.7759/cureus.30330. eCollection 2022 Oct. Cureus. 2022. PMID: 36407159 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous